» Articles » PMID: 3042871

Immunization with Rough Mutants of Salmonella Minnesota: Protective Activity of IgM and IgG Antibody to the R595 (Re Chemotype) Mutant

Overview
Journal J Infect Dis
Date 1988 Aug 1
PMID 3042871
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated the immunoglobulin class responsible for the protective activity in serum obtained from humans and rabbits after immunization with the R595 (Re chemotype) mutant of Salmonella minnesota. Whole serum obtained before immunization and the IgG and IgM fractions failed to protect mice against lethal challenge with viable Klebsiella pneumoniae or Morganella morganii or with Salmonella typhi lipopolysaccharide (LPS). The protective activity of postimmunization serum resided solely in IgM antibody, whereas IgG antibody exhibited no protective activity. IgM antibody to the Re mutant was protective against bacterial challenge with both test strains of bacteria and S. typhi LPS. IgM antibody, at approximately the same concentration present in postimmunization serum, increased the LD50 of K. pneumoniae from less than 8.0 x 10(2) to greater than 2.0 x 10(4). These findings indicate that commercially prepared human IgG with high titers of antibody to antigens of the core portion of LPS would have little clinical utility.

Citing Articles

Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.

Cross A Microbiol Mol Biol Rev. 2023; 87(3):e0004522.

PMID: 37432116 PMC: 10521362. DOI: 10.1128/mmbr.00045-22.


Treatment with IgM-enriched intravenous immunoglobulins enhances clearance of stroke-associated bacterial lung infection.

McCulloch L, Harris A, Malbon A, Daniels M, Younas M, Grainger J Immunology. 2022; 167(4):558-575.

PMID: 35881080 PMC: 11495265. DOI: 10.1111/imm.13553.


Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.

Ali A, An S, Cui C, Haque A, Carbis R Hum Vaccin Immunother. 2014; 10(6):1494-8.

PMID: 24603090 PMC: 5396222. DOI: 10.4161/hv.28130.


Anti-endotoxin vaccines: back to the future.

Cross A Virulence. 2013; 5(1):219-25.

PMID: 23974910 PMC: 3916378. DOI: 10.4161/viru.25965.


Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

Rusthoven J Int J Antimicrob Agents. 1994; 3(4):223-43.

PMID: 18611565 PMC: 7135342. DOI: 10.1016/0924-8579(94)90050-7.